ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Amarin Corporation plc and Encourages Investors with Losses of $100,000 to Contact the FirmNewsfile Corp • 09/02/20
Amarin Supports Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Persistent Cardiovascular Risk Presented at ESC Congress 2020, the Annual Meeting of the European Society of CardiologyGlobeNewsWire • 09/01/20
VASCEPA® (Icosapent Ethyl) Reported to Significantly Reduce Coronary Plaque in EVAPORATE Study Final Results Presented at ESC Congress 2020GlobeNewsWire • 08/29/20
Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2020, the Annual Meeting of the European Society of CardiologyGlobeNewsWire • 08/17/20
Amarin Corporation plc's (AMRN) CEO John Thero on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/04/20
Amarin Reports Mixed Q2 As COVID-19 Weighs On Results; Analyst Sees Favorable Risk-RewardBenzinga • 08/04/20
Amarin Announces Plans to Maximize Blockbuster Potential of VASCEPA® (icosapent ethyl) in EuropeGlobeNewsWire • 08/04/20
Amarin Reports Second Quarter 2020 Financial Results and Provides Update on OperationsGlobeNewsWire • 08/04/20
VASCEPA® (icosapent ethyl) Data from REDUCE-IT® REVASC, Including New Data on Timeframe to Demonstrated Benefit, Presented as Encore at The American Society for Preventive Cardiology 2020 Virtual Summit on CVD (Cardiovascular Disease) PreventionGlobeNewsWire • 07/27/20
Amarin to Report Second Quarter 2020 Results and Host Conference Call on August 4, 2020GlobeNewsWire • 07/21/20